How have NLSPW shares performed in 2024?

NLS Pharmaceutics' stock was trading at $0.0561 at the beginning of the year. Since then, NLSPW stock has decreased by 53.3% and is now trading at $0.0262. View the best growth stocks for 2024 here .

Are investors shorting NLS Pharmaceutics?

NLS Pharmaceutics saw a decline in short interest in April. As of April 15th, there was short interest totaling 100 shares, a decline of 93.3% from the March 31st total of 1,500 shares. Based on an average trading volume of 7,700 shares, the days-to-cover ratio is presently 0.0 days. View NLS Pharmaceutics' Short Interest .

How do I buy shares of NLS Pharmaceutics?

Shares of NLSPW stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:NLSPW

NLS Pharmaceutics (NLSPW) Stock Price, News & Analysis

→ World’s biggest multibillionaire investor is buying THIS by the ton [picture] (From Stansberry Research) (Ad)

Free NLSPW Stock Alerts

$0.03

0.00 (0.00%)

(As of 04/25/2024 ET)

Compare

Today's Range: $0.03
▼
$0.03
50-Day Range: $0.02
▼
$0.09
52-Week Range: $0.01
▼
$0.18

Volume: 1,000 shs
Average Volume: 14,097 shs
Market Capitalization: N/A

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Stock Analysis Chart Competitors Financials SEC Filings Short Interest Social Media

Get NLS Pharmaceutics alerts:

Ad Stansberry Research

World’s biggest multibillionaire investor is buying THIS by the ton [picture]

Don't Buy Bullion or Mining Stocks. Do THIS Instead As gold continues to break all-time highs, many folks will run out and buy bullion or mining stocks. That's not the best way to ride this gold bull market higher. Note, this showed a 995% gain the last time we shared this same investment idea.

Click here to find out what to do.

About NLS Pharmaceutics Stock (NASDAQ:NLSPW)

NLS Pharmaceutics AG, a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies for patients with rare and complex central nervous system disorders. The company is focusing on the development of treatments for narcolepsy, idiopathic hypersomnia, and other rare sleep disorders, as well as neurodevelopmental disorders, such as attention deficit hyperactivity disorder (ADHD). Its lead product candidates include Quilience to treat excessive daytime sleepiness and cataplexy; and Nolazol for the treatment of ADHD. The company also developing NLS-4, a selective dopamine reuptake inhibitor to prevent rare sleep disorders; NLS-3, a repurposed reverse ester of methylphenidate for treatment of ADHD; NLS-8, a melatonin ML1A receptor agonist, improved scopolamine-induced amnesia; NLS-11, a norepinephrine and dopamine reuptake inhibitor and muscarinic M1, M2, M3 receptor antagonist; and NLS-12, a norepinephrine and dopamine reuptake inhibitor and muscarinic M4 receptor antagonist. NLS Pharmaceutics AG was incorporated in 2015 and is based in Zurich, Switzerland.

NLSPW Stock Price History

30 days | 90 days | 365 days | Advanced Chart

NLSPW Stock News Headlines

December 4, 2023 | investorplace.com

Why Is NLS Pharmaceutics (NLSP) Stock Down 24% Today?

November 28, 2023 | finance.yahoo.com

NLS Pharmaceutics Announces Election of Additional Board Members

See More Headlines

Receive NLSPW Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for NLS Pharmaceutics and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Biotechnology
Sub-Industry: N/A
Current Symbol: NASDAQ:NLSPW
CUSIP: N/A
CIK: 1783036
Web: N/A
Phone: 41-44-512-21-50
Fax: N/A
Employees: 7
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): N/A
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: N/A
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: N/A
Return on Assets: N/A

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: N/A
Quick Ratio: N/A

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: N/A
Price / Book: N/A

Miscellaneous

Outstanding Shares: N/A
Free Float: N/A
Market Cap: N/A
Optionable: Not Optionable
Beta: N/A

7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed Investors

As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.

Get This Free Report

Key Executives

Mr. Alexander Zwyer M.B.A. (Age 55)
President, CEO & Director
Comp: $1.07M
Dr. George Apostol M.D. (Age 51)
Chief Medical Officer and Global Head of Research & Development
Comp: $154k
Dr. Eric Konofal M.D. (Age 57)
Ph.D., Co-Founder & Chief Scientific Officer
Ms. Elena Thyen-Pighin
Chief Financial Officer
Dr. Christian C. Wenger Dr. iur. (Age 60)
L.L.M., Ph.D., General Counsel

Key Competitors

View All Competitors

NLSPW Stock Analysis - Frequently Asked Questions

How have NLSPW shares performed in 2024?: NLS Pharmaceutics' stock was trading at $0.0561 at the beginning of the year. Since then, NLSPW stock has decreased by 53.3% and is now trading at $0.0262.
View the best growth stocks for 2024 here.
Are investors shorting NLS Pharmaceutics?: NLS Pharmaceutics saw a decline in short interest in April. As of April 15th, there was short interest totaling 100 shares, a decline of 93.3% from the March 31st total of 1,500 shares. Based on an average trading volume of 7,700 shares, the days-to-cover ratio is presently 0.0 days.
View NLS Pharmaceutics' Short Interest.
How do I buy shares of NLS Pharmaceutics?: Shares of NLSPW stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:NLSPW) was last updated on 4/25/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial